Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02547987 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Mothaffar Rimawi.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT02547987: Active Phase 2 study of Breast Cancer, sponsored by Mothaffar Rimawi.
NCT02547987 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Mothaffar Rimawi. The registered enrollment target is 25 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02547987, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Mothaffar Rimawi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine whether the combination of docetaxel and carboplatin is an effective treatment for patients with triple negative breast cancer.
Primary Outcome
This is the complete disappearance of invasive cancer in the breast at the time of surgery
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
Study Locations (3)
Texas
- Lester & Sue Smith Breast Center at Baylor College of Medicine - Houston
- Harris Health System Smith Clinic - Houston
Ohio
- TriHealth Hatton Research - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-11-01 |
| Est. Completion | 2025-09 |
| Phase | Phase 2 |
What the registry record for NCT02547987 still lists
NCT02547987 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Carboplatin is the first listed.
NCT02547987 reports a single indexed study location in Texas, Ohio.
Frequently Asked Questions
What is clinical trial NCT02547987 about?
NCT02547987 is a clinical study titled "Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer". The purpose of this study is to determine whether the combination of docetaxel and carboplatin is an effective treatment for patients with triple negative breast cancer.
What is the current status of trial NCT02547987?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2015-11-01. Estimated completion is 2025-09.
What conditions does trial NCT02547987 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02547987?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG).
Who is sponsoring clinical trial NCT02547987?
This trial is sponsored by Mothaffar Rimawi, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02547987 being conducted?
This trial has 3 study locations across Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02547987's enrollment target sits among peer trials
25 1031st of 1224 higher than 184 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI